TrialResults-center.org

Menu

relaxine
Description Results NMA

Group by...

in first

in second

in third

pathology

treatment

patient

Demonstrated benefit and harm

k

heart failure

serelaxin

not classified

versus placebo or control

No demonstrated result for efficacy

Trial	control	p<0.05	harm	NS
Pre-RELAX-AHF, 2009	serelaxin vs placebo

Trial

Treatments

Patients

Method

Pre-RELAX-AHF, 2009

intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily (n=172)

vs.

placebo (n=62)

Patients hospitalized with acute heart failure

double blind

Parallel groups

Sample size: 172/62

Primary endpoint: none defined

FU duration:

dose-finding phase IIb study

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -